Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16218016 | 0.89 | KDM4E (0.50) | ALDH1A1 | |
| SCHEMBL10069100 | 0.87 | BACE1 (0.49) | ALDH1A1MAPTGAASMN1; SMN2 | |
| SCHEMBL30725419 | 0.87 | BACE1 (0.49) | ALDH1A1MAPTGAASMN1; SMN2 | |
| SCHEMBL9955066 | 0.86 | PRMT1 (0.60) | ALDH1A1MAPT | |
| SCHEMBL30725472 | 0.85 | MAOB (0.45) | ALDH1A1 | |
| SCHEMBL29174566 | 0.85 | MAOB (0.45) | ALDH1A1 | |
| SCHEMBL29174559 | 0.81 | NR1H4 (0.63) | ALDH1A1MAPTGAA | |
| SCHEMBL30725450 | 0.81 | NR1H4 (0.63) | ALDH1A1MAPTGAA | |
| SCHEMBL9954861 | 0.81 | ALDH1A1 (0.47) | ALDH1A1MAPTMEN1NPC1KMT2A | |
| Hydrochloric Acid SCHEMBL28059090 | 0.77 | HTR6 (0.40) | ALDH1A1MAPTNPC1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2655365-B1 | 2-CARBOXAMIDE-4-PIPERAZINYL-BENZOFURAN DERIVATIVE | Acturum Life Science AB (SE) | 2015-12-16 | — | — | EP | disclosed |
| US-9012457-B2 | 2-carboxamide-4-piperazinyl-benzofuran derivative | ASTRAZENECA AB (SE) | 2015-04-21 | — | — | US | disclosed |
| US-20140329830-A1 | 2-CARBOXAMIDE-4-PIPERAZINYL-BENZOFURAN DERIVATIVE | ASTRAZENECA AB (SE) | 2014-11-06 | — | — | US | disclosed |
| EP-2655365-A1 | 2-CARBOXAMIDE-4-PIPERAZINYL-BENZOFURAN DERIVATIVE | AstraZeneca AB (SE) | 2013-10-30 | — | — | EP | disclosed |
| WO-2012087229-A1 | 2-CARBOXAMIDE-4-PIPERAZINYL-BENZOFURAN DERIVATIVE | ASTRAZENECA AB (SE) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140329830-A1 | 2-CARBOXAMIDE-4-PIPERAZINYL-BENZOFURAN DERIVATIVE | GRIN2C, BDNF, GRIN2A | ALDH1A1 436/4885MAPT 30/4885MEN1 3872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.